The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and ...

The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...

GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains ...

With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

Moderna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions.

Recent health news includes Donald Trump's consideration of an executive order on gas stoves, Roche's acquisition of Poseida, ...

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

The global pediatric vaccine market is set for unprecedented growth, with a valuation of US$ 54,130.1 million in 2023, ...